Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies (Q38639264)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

James M. Brophy

object named as

James M Brophy

2

0 references

author name string

Tanja Tran

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Samy Suissa

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Christel Renoux

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

985-998

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Clinical practice. Diagnosis and initial management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

The frequency of cardiac valvular regurgitation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Bromocriptine use and the risk of valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of heart failure associated with dopamine agonists: a nested case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Fibrotic valvular heart disease subsequent to bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Agonism at 5-HT2B receptors is not a class effect of the ergolines

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Drugs and valvular heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Coronary artery disease as the cause of incident heart failure in the population

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Epidemiology, aetiology, and prognosis of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Dopamine agonist use and the risk of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0293-4

21 January 2018

Multiple valvular regurgitation associated with bromocriptine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine agonist therapy in early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pergolide associated cardiac valvulopathy based on Ontario administrative data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26585874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-015-0293-4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38639264&oldid=2201911501"